CareDx, Inc (CDNA) Stock

CareDx, Inc (CDNA) is a Healthcare stock trading at $26.20 (as of 2026-06-18), with a market capitalization of $1.18B and a trailing P/E of -145.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

CareDx, Inc. provides diagnostic solutions used in transplant care, including dd-cfDNA and gene-expression tests to monitor patients after kidney, heart, and lung transplantation, as well as HLA typing and chimerism testing for transplant recipients. It also offers transplant management and quality tracking software for patients, caregivers, and clinical teams.

Valuation — source: SEC EDGAR (first-party)
Price$26.20
Market Cap$1.18B
P/E Ratio-145.3
EV / EBITDA-1258.5
Price / Book3.83
Price / Sales2.91
DCF Value (model)$15.26
DCF Upside vs Price-41.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$379.81M
Net Margin-5.6%
Return on Equity-2.6%
Current Ratio3.40
Revenue Growth (YoY)13.8%
EPS Growth (YoY)-140.0%
Financial Health — source: SEC EDGAR
Altman Z-Score5.98 (safe)
Valuation vs Sector & Industry
Stock P/E-145.3
Sector P/E (Healthcare)21.0
Industry P/E (Healthcare Services)23.0
vs Sector-793.3%
vs Industry-730.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($78.50M)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorHealthcare
IndustryHealthcare Services
CEOJohn Walter Hanna Jr.
Employees644
CountryUS
IPO Date2014-07-17

Related Companies (Business model: Clinical Labs / CRO Services; 8 closest by market cap; US-domiciled)

  • BillionToOne, Inc. (BLLN)
  • Fortrea Holdings Inc. (FTRE)
  • Anbio Biotechnology Class A Ordinary Shares (NNNN)
  • Neogen Corporation (NEOG)
  • Castle Biosciences, Inc. (CSTL)
  • Fulgent Genetics, Inc. (FLGT)
  • Personalis, Inc. (PSNL)
  • Myriad Genetics, Inc. (MYGN)
CDNA earnings history · CDNA institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.